VCYT
VCYT
US92337F1075
Veracyte, Inc.
Loading chart...

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Latest News

Related stocks

BLLN
BLLN • United States
BillionToOne, Inc.
98.09 USD
4.63B USD
ADPT
ADPT • United States
Adaptive Biotechnologies Corpor
26.49 USD
4.23B USD 1Y +67.8%
SHC
SHC • United States
Sotera Health Company
18.06 USD
5.15B USD 1Y +11.4%
WGS
WGS • United States
GeneDx Holdings Corp.
67.33 USD
2.01B USD 1Y -44.8%
CDNA
CDNA • United States
CareDx, Inc.
63.67 USD
3.29B USD 1Y +320.6%
NEO
NEO • United States
NeoGenomics, Inc.
16.35 USD
2.13B USD 1Y +74.7%
RDNT
RDNT • United States
RadNet, Inc.
70.91 USD
5.58B USD 1Y -10.3%
PSNL
PSNL • United States
Personalis, Inc.
16 USD
1.71B USD 1Y +85%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
64.8% p.a.
Max Drawdown (5Y)
-71.5%
Sharpe Ratio (5Y)
-0.02
Beta Factor
1.95
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 1.95 indicates above-average volatility compared to the broader market.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (64.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -81.2% in the extended horizon.
ende